Nurix Doses First Patient in Bexobrutideg Phase 3 Trial

The Tip Desk · October 13, 2026 · 3 min read

The company booked $673.1 million of third-quarter revenue after closing the Roche deal and dosing the first patient in DAYBreak CLL-306.

Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company developing targeted protein-degradation medicines, closed its global bexobrutideg collaboration with Roche in the fiscal third quarter, cleared Hart-Scott-Rodino review, and dosed the first patient in DAYBreak CLL-306, the first Phase 3 trial of the BTK degrader.

The registrational study is a global, randomized comparison of bexobrutideg 600 mg once daily with pirtobrutinib in about 620 patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma whose disease progressed after a covalent BTK inhibitor. Dual primary endpoints are objective response rate and progression-free survival, each read by an independent review committee. The design is intended to support global regulatory submissions. Enrollment continued in DAYBreak CLL-201, a pivotal single-arm Phase 2 trial aimed at a potential Accelerated Approval filing in a later-line CLL population.

President and chief executive Arthur T. Sands said the quarter marked a transition as Nurix moved bexobrutideg into Phase 3 in CLL and began executing a broader clinical strategy across oncology and autoimmune disease.

Under the Roche agreement, development costs are shared 40% by Nurix and 60% by Roche, U.S. profits and losses are split equally, and Nurix is eligible for tiered royalties on ex-U.S. sales. The collaboration spans malignant hematology, immunology and neurology, including planned expansion into chronic spontaneous urticaria and multiple sclerosis. Nurix also began recruiting in Phase 1b/2 study NX-5948-203, with an initial cohort combining bexobrutideg with venetoclax.

Revenue for the three months ended August 31, 2026, was $673.1 million, compared with $7.9 million a year earlier. The increase was primarily $653.2 million of license revenue from Roche and a $10.0 million Sanofi development milestone. Collaboration revenue was $19.9 million.

Net income was $549.8 million, or $4.73 a share on a diluted basis, versus a net loss of $86.4 million, or ($1.03) a share, a year earlier. Research and development expenses were $79.3 million, primarily due to a cost-sharing offset from Roche. General and administrative expenses were $34.4 million, primarily due to one-time Roche-transaction consulting and business-development costs.

Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, after the $700 million Roche upfront. Runway extends into the second half of 2029.

Sanofi initiated a Phase 1 first-in-human trial of the oral STAT6 degrader SAR448272/NX-3911, triggering the $10 million milestone. Following that payment, Nurix has earned about $139 million under the Sanofi collaboration and remains eligible for about $455 million in future development, regulatory and commercial milestones, plus potential royalties. The company retains an option to co-develop and share U.S. profits and losses equally after clinical proof of concept. Gilead continues a first-in-human Phase 1 study of the IRAK4 degrader GS-6791.

On the wholly owned oncology portfolio, Nurix advanced the oral CBL-B inhibitor NX-1607 into Phase 1b monotherapy expansion cohorts in microsatellite-stable colorectal cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer and melanoma, and into a Phase 1a combination cohort with pembrolizumab, dosing the first patient in both in September 2026. Each tumor-specific expansion cohort is planned to enroll about 30 patients.

The company also announced a $7 million milestone under its Pfizer collaboration and agreed with Gilead to extend the research term for one oncology program by two years for a $10.0 million one-time fee. Together with the Sanofi milestone, those items contributed to $27 million earned from Gilead, Pfizer and Sanofi collaborations.

Nurix decided to discontinue further clinical development of NX-2127 (zelebrudomide) as part of a strategic prioritization of its wholly owned oncology portfolio. Patients already receiving the drug may continue treatment for as long as clinically appropriate, with safety monitoring and institution-level follow-up.

The company completed a single-ascending-dose and multiple-ascending-dose study of a new bexobrutideg tablet formulation in healthy volunteers to support future development in immunology and neurology.